BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Metabolex, Inc. 

3876 Bay Center Place

Hayward  California  94545  U.S.A.
Phone: 510-293-8800 Fax: 510-293-9090


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology


Collaborations

Yamanouchi Pharmaceutical Co., Ltd. 

Abbott Laboratories 

Devgen NV  Signed in 2001; research collaboration focused on diabetes; both companies each employ their respective technologies to identify each others compounds' mechanism of action.





 Company News
Metabolex, Inc. Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat 12/8/2011 7:19:24 AM
Metabolex, Inc. Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 11/29/2011 12:22:32 PM
Metabolex, Inc. to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011ACR/ARHP Annual Scientific Meeting 11/1/2011 10:43:57 AM
Metabolex, Inc. Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer 10/20/2011 11:29:40 AM
Metabolex, Inc. Initiates Phase 2 Trial of Arhalofenate 5/19/2011 9:00:36 AM
Sanofi-Aventis (France) (SASY.PA) Opts Out of Metabolex, Inc. Diabetes Drug Deal; Deal Could Have Been Worth up to $375 Million 5/6/2011 7:24:55 AM
Metabolex, Inc. to Conduct a Webcast of Its Second Quarter 2010 Earnings Call 7/16/2010 10:14:16 AM
Sanofi-Aventis (France) (SASY.PA) Inks $375 Million Diabetes Deal With Metabolex, Inc. 6/25/2010 6:53:18 AM
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million 6/22/2010 7:15:21 AM
Metabolex, Inc. Initiates Research Collaboration with Takeda Pharmaceutical Co. Ltd. (TKDG.DE) 4/13/2010 9:19:26 AM
123456